Skip to content
  • BTC $58,830 −6.8%
  • ETH $1,629 −8.8%
  • SOL $69.06 −7.4%
  • BNB $541.52 −8.1%
  • XRP $0.9075 −7.3%
  • DOGE $0.0541 −8.5%
  • ADA $0.1409 −8.6%

EyePoint stock (EYPT)

Sustained-release retinal therapies: EyePoint between phase 3 trials and Cryptonomist analyses.

Stock profile

Symbol
EYPT
Listing
NASDAQ
Sector
Healthcare
Currency
USD
Analyses published
1
First analysis

Prices are not shown on this page: you will find them in each analysis, with the trading session they refer to.

Latest analysis ·

EyePoint, Inc. stock rebounds to $4.62 but stays deep in a bearish trend

EyePoint, Inc. stock is showing one of its most stressed technical setups in recent memory. The stock closed at $4.62 after opening at $4.03, with a $3.98 low and a $4.70 high. That range signals an aggressive oversold rebound, yet the higher-timeframe trend remains firmly…

Read the analysis

About EyePoint

EyePoint is an American biopharmaceutical company based in Massachusetts and listed on the Nasdaq, specializing in therapies for retinal disease. Its strength is sustained-release drug delivery: a tiny insert injected into the eye can release the active ingredient for months, cutting the number of injections patients need. Its flagship program is Duravyu, a vorolanib insert for neovascular age-related macular degeneration and diabetic macular edema, and the company also has approved products that are marketed directly or licensed to partners.

What moves the stock

As with nearly all biotech names, the stock moves mainly on clinical and regulatory news. Phase 3 trial results, discussions with the FDA, a possible approval and the ability to compete with established drugs that require more frequent injections all count. Licensing agreements with industry partners, the cash available to fund trials and the chance of new capital raises weigh as well. General sentiment toward the biotech sector and interest rates also influences the swings. Because a single trial outcome can change how the market values the whole pipeline, investors tend to treat each announced milestone as an event of its own.

How to read Cryptonomist’s analyses

A sustained-release retinal drug lives on phase 3 trials, so the price moves in jumps around the data and communications from the FDA. The daily chart shows the levels left by those jumps; the hourly one shows whether the first reaction consolidates or fades in the next session, which is especially useful given how crowded the field is.

All analyses on EyePoint

Other stocks

Informational content, not financial advice or an invitation to invest.